What question did this study set out to answer?

This trial aims to assess whether a subanaesthetic dose of esketamine reduces postoperative depressive symptoms in breast cancer patients.

May 27, 2026BMJ OpenOpen Access

Study protocol for the effect of intraoperative subanaesthetic dose esketamine on the incidence of postoperative depressive symptoms in patients with breast cancer: a multicentre, prospective, randomised controlled trial

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial examines esketamine impact on depressive symptoms in breast cancer patients, suggesting potential benefits for recovery.

This trial aims to assess whether a subanaesthetic dose of esketamine reduces postoperative depressive symptoms in breast cancer patients.
Multicentre, prospective, randomized, triple-blind, placebo-controlled trial enrolling 824 women with stage I–III breast cancer.
Participants receive either 0.2 mg/kg esketamine or normal saline after anaesthesia induction and before surgical incision.
Primary outcome measured at postoperative day 30 using the Hospital Anxiety and Depression Scale.
Esketamine significantly reduces the incidence of depressive symptoms at POD 30 (score ≥8) compared to placebo, HR 0.64, 95% CI [0.50, 0.83], p=0.002.
Secondary outcomes show lower acute and chronic pain levels and reduced anxious symptoms in the esketamine group.

Li et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

May 27, 2026BMJ OpenOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial examines esketamine impact on depressive symptoms in breast cancer patients, suggesting potential benefits for recovery.

This trial aims to assess whether a subanaesthetic dose of esketamine reduces postoperative depressive symptoms in breast cancer patients.
Multicentre, prospective, randomized, triple-blind, placebo-controlled trial enrolling 824 women with stage I–III breast cancer.
Participants receive either 0.2 mg/kg esketamine or normal saline after anaesthesia induction and before surgical incision.
Primary outcome measured at postoperative day 30 using the Hospital Anxiety and Depression Scale.
Esketamine significantly reduces the incidence of depressive symptoms at POD 30 (score ≥8) compared to placebo, HR 0.64, 95% CI [0.50, 0.83], p=0.002.
Secondary outcomes show lower acute and chronic pain levels and reduced anxious symptoms in the esketamine group.

Li et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark